6533b7d3fe1ef96bd12608dc
RESEARCH PRODUCT
CONKO-005: Adjuvant therapy in R0 resected pancreatic cancer patients with gemcitabine plus erlotinib versus gemcitabine for 24 weeks—A prospective randomized phase III study.
Dirk WaldschmidtHanno RiessRobert GrützmannJana K. StrieflerHelmut MessmannUwe PelzerKlaus GellertGeorg MaschmeyerTorsten LierschJens StielerMartin WilhelmMarcus BahraBettina RauWolf O. BechsteinHelmut OettleLutz JacobaschB. Michael GhadimiArndt WeinmannBernd DörkenMarianne Sinnsubject
Oncology0303 health sciencesCancer Researchmedicine.medical_specialtyendocrine system diseasesAdjuvant chemotherapybusiness.industrymedicine.diseaseGemcitabine3. Good health03 medical and health sciences0302 clinical medicineOncology030220 oncology & carcinogenesisPancreatic cancerInternal medicinemedicineAdjuvant therapyErlotinibbusiness030304 developmental biologymedicine.drugdescription
4007 Background: Adjuvant chemotherapy with gemcitabine (Gem) for 6 months significantly improves survival of pancreatic cancer patients. CONKO-005 was designed to evaluate an additional effect of ...
year | journal | country | edition | language |
---|---|---|---|---|
2015-05-20 | Journal of Clinical Oncology |